Cargando…

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby restoring normal tissue function(1–3). The interaction of menin with lysine methyltransferase 2A (KMT2A), an epigenetic regulator, is a dependence in acute leukaemia caused by either rearrangement of KMT2A or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Issa, Ghayas C., Aldoss, Ibrahim, DiPersio, John, Cuglievan, Branko, Stone, Richard, Arellano, Martha, Thirman, Michael J., Patel, Manish R., Dickens, David S., Shenoy, Shalini, Shukla, Neerav, Kantarjian, Hagop, Armstrong, Scott A., Perner, Florian, Perry, Jennifer A., Rosen, Galit, Bagley, Rebecca G., Meyers, Michael L., Ordentlich, Peter, Gu, Yu, Kumar, Vinit, Smith, Steven, McGeehan, Gerard M., Stein, Eytan M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060155/ https://www.ncbi.nlm.nih.gov/pubmed/36922593 http://dx.doi.org/10.1038/s41586-023-05812-3

Ejemplares similares

P561: REVUMENIB IN PATIENTS WITH ACUTE LEUKEMIAS: COMPASSIONATE USE PROGRAM EXPERIENCE
por: Rubnitz, Jeffrey, et al.
Publicado: (2023)

Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model
por: Carter, Bing Z., et al.
Publicado: (2023)

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
por: Fiskus, Warren, et al.
Publicado: (2022)

Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes
por: Sparbier, Christina E., et al.
Publicado: (2023)

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1
por: Mill, Christopher P., et al.
Publicado: (2023)

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
por: Fiskus, Warren, et al.
Publicado: (2023)

Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets
por: Lin, Wenchu, et al.
Publicado: (2016)

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
por: Issa, Ghayas C., et al.
Publicado: (2021)

Menin is necessary for long term maintenance of meningioma-1 driven leukemia
por: Libbrecht, Clara, et al.
Publicado: (2021)

The MLL–Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML
por: Rasouli, Milad, et al.
Publicado: (2023)

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
por: Heikamp, Emily B., et al.
Publicado: (2022)

S125: NON-GENETIC RESISTANCE TO MENIN INHIBITION IN AML IS REVERSIBLE BY PERTURBATION OF KAT6A
por: Perner, Florian, et al.
Publicado: (2023)

IKAROS and MENIN Coordinate Therapeutically Actionable Leukaemogenic Gene Expression in MLL-r Acute Myeloid Leukaemia
por: Aubrey, Brandon J., et al.
Publicado: (2022)

Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
por: Ling, Qing, et al.
Publicado: (2023)

Menin and Menin-Associated Proteins Coregulate Cancer Energy Metabolism
por: Chou, Chih-Wei, et al.
Publicado: (2020)

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1
por: Fiskus, Warren, et al.
Publicado: (2022)

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2021)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

P410: COMBINING MENIN AND MEK INHIBITION TO TREAT CHILDREN WITH POOR PROGNOSTIC KMT2A-R RAS-MUTANT ACUTE LEUKEMIA
por: Scheidegger, Nastassja, et al.
Publicado: (2023)

Breakthrough treatment choice for Acute Myeloid Leukemia in pediatric and adult patients: Revumenib, an oral selective inhibitor of KMTA2Ar
por: Fareed, Areeba, et al.
Publicado: (2023)

A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1
por: Numata, Masashi, et al.
Publicado: (2023)

The role of menin in bone pathology
por: Gorbacheva, Anna, et al.
Publicado: (2022)

Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax
por: Rausch, Johanna, et al.
Publicado: (2023)

FBP1 Is an Interacting Partner of Menin
por: Zaman, Shadia, et al.
Publicado: (2014)

Menin: Expanding and dichotomous roles in cancer
por: Katona, Bryson W., et al.
Publicado: (2019)

Endotracheal Involvement as an Unusual Extranodal Site of Recurrence from Mantle Cell Lymphoma
por: Verde, Franco, et al.
Publicado: (2015)

The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia
por: Nazha, Aziz, et al.
Publicado: (2013)

Investigating the novel-binding site of RPA2 on Menin and predicting the effect of point mutation of Menin through protein–protein interactions
por: Kaur, Gurjeet, et al.
Publicado: (2023)

A case of KMT2A–SEPT9 fusion–associated acute megakaryoblastic leukemia
por: Forlenza, Christopher J., et al.
Publicado: (2018)

Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
por: Loghavi, Sanam, et al.
Publicado: (2014)

Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target
por: Brzezinka, Krzysztof, et al.
Publicado: (2020)

Investigating the Effects of Amino Acid Variations in Human Menin
por: Biancaniello, Carmen, et al.
Publicado: (2022)

Hypothalamic Menin regulates systemic aging and cognitive decline
por: Leng, Lige, et al.
Publicado: (2023)

Development of an orally bioavailable selective inhibitor of the menin-MLL
por: Zhong, Hai-Jing, et al.
Publicado: (2022)

Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis
por: McDuff, Fiona Kate Elizabeth, et al.
Publicado: (2011)

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
por: Bidikian, Aram, et al.
Publicado: (2022)

Management of chronic myeloid leukemia in 2023 – common ground and common sense
por: Senapati, Jayastu, et al.
Publicado: (2023)

Structural Analysis of Mitochondrial Mutations Reveals a Role for Bigenomic Protein Interactions in Human Disease
por: Lloyd, Rhiannon E., et al.
Publicado: (2013)

Multi-omics analyses of MEN1 missense mutations identify disruption of menin–MLL and menin–JunD interactions as critical requirements for molecular pathogenicity
por: Dreijerink, Koen M. A., et al.
Publicado: (2022)

A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin–MLL Inhibition
por: Soto-Feliciano, Yadira M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_anbub3le1amhci2uip6nqcjovs